Abstract
Amyloidosis is a disease characterized by extracellular deposition of misfolded proteins, causing progressive organ damage, including end-stage kidney disease (ESKD). Patients with ESKD due to amyloidosis face poor survival rates, and evidence to guide optimal management strategies is lacking. We present the case of a 64-year-old woman with hereditary transthyretin (TTR) amyloidosis and ESKD who has been successfully treated with peritoneal dialysis (PD) for over 33 months. This report highlights the challenges encountered during follow-up, including the progression of peripheral neuropathy, and underscores the need for further investigation leading to targeted therapies to prevent disease progression and complications.